繁體
简体中文
繁體中文

Columbia Research Enhanced Core Premium Income ETF RECI 深 滬

已收盤 11-20 16:00:00 美东时间

18.9225

-0.493

-2.54%

华盛通華盛通
立即下載
  • 最 高18.9225
  • 今 開19.416
  • 成交量 12股
  • 最 低 18.9225
  • 昨 收 19.416
  • 總市值 946.22万
  • 52周最高 20.5777
  • 市盈率 靜 --
  • 換手率 0.00%
  • 52周最低 18.9225
  • 委 比 0.00%
  • 總股本 50.01万
  • 歷史最高 20.5777
  • 量 比 0
  • 振 幅 0.00%
  • 歷史最低 18.9225
  • 每 手 1
  • 風險率 0.33%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts

    Allarity Therapeutics expands eligibility for its Phase 2 stenoparib trial in advanced ovarian cancer to include patients with primary platinum-refractory disease and those with hard-to-measure but clinically evaluable disease. This expansion follows encouraging early results, including durable clinical benefit and extended survival, and aims to evaluate stenoparib's potential across a broader patient population. The trial now includes three pati...

    11-16 12:50

  • Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

    Sutro Biopharma reported progress in its ADC pipeline, with STRO-004 and STRO-006 entering clinical trials and STRO-227 advancing toward early 2027 development. The company also received a $10 million milestone payment from Astellas for initiating a second dual-payload iADC program. Sutro's cash reserves of $142.2 million are expected to support operations into 2028. CEO Jane Chung highlighted the potential of the company's ADC platform to delive...

    11-12 21:30

  • Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates

    Iovance Biotherapeutics reported a record third quarter 2026 with ~$122 million in revenue, up 80% year-over-year, and a gross margin of ~60%. U.S. Amtagvi revenue grew 77% YoY to ~$102 million. The company achieved a 24.6% objective response rate (ORR) in 69 patients with non-squamous metastatic non-small-cell lung cancer (mNSCLC) and a 59.1% ORR in a biomarker-selected subgroup. The SARATOGA trial for undifferentiated pleomorphic sarcoma (UPS) ...

    11-05 12:00

  • Aprea Therapeutics Announces Third Quarter 2026 Financial Results

    Aprea Therapeutics reported Q3 2026 financial results with $37.8 million in cash and provided updates on its WEE1 inhibitor APR-1051, which is advancing in a Phase 1 clinical trial expanded to nine sites. The company plans to present interim Phase 1 data at the EORTC-NCI-AACR Symposium in November 2026 and expects to select the dose for Part 2 in early 2027. APR-1051 is being evaluated in biomarker-defined cancers, with a focus on endometrial can...

    11-04 13:30

  • Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

    Iovance Biotherapeutics announced that lifileucel monotherapy achieved a 50% confirmed ORR in a pilot trial for metastatic UPS and DDLPS at the ESMO Congress 2026. All four partial responses were ongoing as of September 2026. The safety profile was consistent with previous studies, and the FDA granted fast track designation for lifileucel in advanced UPS and DDLPS. The SARATOGA trial is now enrolling patients to support new approvals, highlightin...

    10-26 11:00

  • Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

    Zentalis Pharmaceuticals announced interim OS data from the DENALI Part 1b study for azenosertib in platinum-resistant ovarian cancer (PROC). Cyclin E1-positive patients (n=48) had a median OS of 15.8 months, compared to 7.5 months in Cyclin E1-negative patients (n=46). No new safety signals were observed. The data will be presented at the ESMO Congress 2026 on October 23. Azenosertib is being further developed in DENALI Part 2 and the ASPENOVA P...

    10-18 22:05

  • Apple Is The Most Underappreciated AI Mega-Cap, Analyst Says

    Apple Inc (NASDAQ:AAPL) stock gained almost 3% on Wednesday as buyers lean into large-cap strength despite a softer tape in Technology. The Nasdaq is up 0.13% while the S&P 500 has gained 0.53%, even as the Technology sector is down 0.6%. The Big Tech giant is balancing regulatory changes in Europe,...

    08-20 00:34